Skip to main content

Table 2 Details of observed drug mutations and prediction of resistance to ARVs according to ANRS algoritm (version July 2010) and corresponding patient characteristics, CD4 counts and viral load values

From: High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo

Patient

Age

Sex

CD4 (cells/mm3)

Viral

Drug-resistance Mutations

Predicition of high level resistance to following ARVs

ID

  

M0

M12

load

NRTI (ex 3TC/FTC)

3TC/FTC

NNRTI

 

T3003

28

F

175

50

5.68

M41LM,T215NSTY,V75MV

M184V

Y181C

EFV/NVP; 3TC/FTC, D4T, AZT

T3008

32

F

70

36

5.57

K65R, (T69D)

-

K101E, Y181C, G190S

EFV/NVP; TDF

T3013

23

F

nt

507

4.75

T69N

-

K103N, Y181C

EFV/NVP

T3017

68

M

53

203

4.88

-

M184V

(A98AG), K103KN,

EFV/NVP; 3TC/FTC

T3029

39

M

21

145

6.34

-

M184V

K101E, G190A,

EFV/NVP; 3TC/FTC

T3031

36

M

100

21

4.20

M41L, T215Y, V75MV,

M184V

Y181C

EFV/NVP; 3TC/FTC, D4T, AZT

T3034

39

M

154

209

4.59

-

M184V

Y181C

EFV/NVP; 3TC/FTC

T3039

33

F

181

264

5.08

-

M184V

Y181V

ETV, EFV/NVP; 3TC/FTC

T3041

47

M

348

218

4.99

-

M184V

K101E, G190A

EFV/NVP; 3TC/FTC

T3042

35

F

16

17

5.23

T69N, Q151M

M184V

V90I, K103N, Y181C, G190A

EFV/NVP; 3TC/FTC, ABC, AZT, D4T, DDI,

T3043

37

F

276

255

4.89

-

M184V

K103N

EFV/NVP; 3TC/FTC

T3046

43

M

36

43

4.64

K70R, T215F, K219E

M184V

Y181C

EFV/NVP; 3TC/FTC, AZT, D4T

T3047

32

M

128

254

4.41

-

-

Y181C, H221HY

ETV, EFV/NVP

T3049

33

F

154

338

4.25

-

M184V

G190A

EFV/NVP; 3TC/FTC

T3061

24

F

184

410

3.43

-

M184V

V106A,

NVP; 3TC/FTC

T3067

37

F

143

264

3.32

T69S

M184V

K103N,

EFV/NVP; 3TC/FTC

T3069

40

M

143

163

3.72

T69D, K70R, K219Q

M184V

Y181C, G190A, H221Y

ETV, EFV/NVP; 3TC/FTC

T3071

40

F

80

282

3.43

T69N

M184V

Y181C

EFV/NVP; 3TC/FTC

T3073

45

M

168

58

4.08

-

-

K103N, Y181C

EFV, NVP

E5009

35

M

78

43

5.56

D67N, K65R

-

V106M, Y188C

EFV/NVP; TDF

E5011

50

M

102

148

3.32

-

M184V

Y181C

EFV/NVP; 3TC/FTC

E5013

32

F

57

112

3.20

T69N

M184V

Y181C

EFV/NVP; 3TC/FTC, DDI

E5016

33

F

173

399

4.20

-

-

Y181CY

EFV/NVP

E5017

47

M

nt

182

4.23

-

M184V

Y181V

ETV; 3TC/FTC

E5020

22

F

147

365

3.04

-

M184V

K103N

EFV/NVP; 3TC/FTC

E5024

42

M

78

197

4.41

-

M184V

(V90I), V106A,

EFV/NVP; 3TC/FTC

E5025

48

F

51

71

3.32

K65R

-

Y181C, K103N

EFV/NVP; TDF

E5027

29

F

35

84

5.08

-

-

K103KN

EFV/NVP

E5032

39

M

70

13

5.45

-

-

G190AG, K103N

EFV/NVP

E5043

46

M

27

93

3.11

-

M184V

Y181V, (A98S)

ETV; 3TC/FTC

E5044

60

F

nt

517

4.78

-

M184V

Y188L

EFV/NVP; 3TC/FTC

E5047

52

F

57

57

4.54

-

-

Y181C, K103N

EFV/NVP

E5053

35

M

99

66

5.74

(D67N, L210W)

-

Y181C, G190AG, (V90I)

EFV/NVP

E5059

41

M

118

40

4.59

(T69N )

-

Y181C

EFV/NVP

E5061

31

F

34

72

4.72

M41L

M184I,

Y181C, V90IV, A98AG, H221Y

ETV, EFV/NVP; 3TC/FTC

E5068

30

F

152

339

3.15

-

M184V

K103N, (A98G)

EFV/NVP; 3TC/FTC

C7003

34

M

98

288

4.30

-

M184V

V106A,

NVP; 3TC/FTC

C7004

38

F

185

540

4.45

-

M184V

K103N, Y181C, (V90IV)

EFV,NVP; 3TC/FTC

C7012

40

M

75

267

3.23

-

M184V

Y181C

EFV/NVP; 3TC/FTC

C7017

42

M

12

40

4.98

-

-

K103N

EFV/NVP

C7022

31

F

64

310

4.08

-

M184V

Y181C

EFV/NVP; 3TC/FTC

C7023

27

F

101

83

3.36

-

M184MV

K103N, (A98AG)

EFV/NVP; 3TC/FTC

C7024

20

F

35

84

4.00

T69D, D67G, K70R, K219Q

M184V

Y181C, G190A, H221Y

ETV, EFV/NVP; 3TC/FTC, AZT, DDI

C7028

33

M

72

12

4.36

-

-

Y181C, K103N

EFV/NVP

C7030

30

F

190

603

3.51

-

-

G190AG

EFV/NVP

C7044

55

F

nt

204

3.38

-

M184V

Y181C, H221Y

ETV, EFV/NVP; 3TC/FTC

  1. Viral load is expressed as log10 copies/ml. The abbreviations are for the following drugs: AZT - zidovudine; 3TC - lamivudine; FTC - emtricitabine; ddI - didanosine; d4T - stavudine; ABC - abacavir; TDF - tenofovir; EFV - efavirenz; NVP - nevirapine; ETV - etravirine